MSFT   182.85 (-0.22%)
FB   229.48 (+1.95%)
GOOGL   1,433.63 (+0.01%)
AMZN   2,470.89 (+1.17%)
CGC   16.31 (-6.10%)
BABA   206.28 (-0.54%)
MU   46.79 (-2.34%)
GE   6.70 (+1.83%)
AMD   53.61 (-0.35%)
T   31.07 (+0.68%)
GILD   75.00 (-3.64%)
DIS   118.74 (+1.23%)
NFLX   422.82 (+0.74%)
BAC   24.58 (+1.91%)
MSFT   182.85 (-0.22%)
FB   229.48 (+1.95%)
GOOGL   1,433.63 (+0.01%)
AMZN   2,470.89 (+1.17%)
CGC   16.31 (-6.10%)
BABA   206.28 (-0.54%)
MU   46.79 (-2.34%)
GE   6.70 (+1.83%)
AMD   53.61 (-0.35%)
T   31.07 (+0.68%)
GILD   75.00 (-3.64%)
DIS   118.74 (+1.23%)
NFLX   422.82 (+0.74%)
BAC   24.58 (+1.91%)
MSFT   182.85 (-0.22%)
FB   229.48 (+1.95%)
GOOGL   1,433.63 (+0.01%)
AMZN   2,470.89 (+1.17%)
CGC   16.31 (-6.10%)
BABA   206.28 (-0.54%)
MU   46.79 (-2.34%)
GE   6.70 (+1.83%)
AMD   53.61 (-0.35%)
T   31.07 (+0.68%)
GILD   75.00 (-3.64%)
DIS   118.74 (+1.23%)
NFLX   422.82 (+0.74%)
BAC   24.58 (+1.91%)
MSFT   182.85 (-0.22%)
FB   229.48 (+1.95%)
GOOGL   1,433.63 (+0.01%)
AMZN   2,470.89 (+1.17%)
CGC   16.31 (-6.10%)
BABA   206.28 (-0.54%)
MU   46.79 (-2.34%)
GE   6.70 (+1.83%)
AMD   53.61 (-0.35%)
T   31.07 (+0.68%)
GILD   75.00 (-3.64%)
DIS   118.74 (+1.23%)
NFLX   422.82 (+0.74%)
BAC   24.58 (+1.91%)
Log in

NASDAQ:NTLAIntellia Therapeutics Stock Price, Forecast & News

$19.79
+2.28 (+13.02 %)
(As of 06/1/2020 12:50 PM ET)
Add
Compare
Today's Range
$18.93
Now: $19.79
$20.66
50-Day Range
$12.47
MA: $15.38
$20.99
52-Week Range
$9.18
Now: $19.79
$21.63
Volume1.31 million shs
Average Volume905,128 shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.72
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Ospedale San Raffaele; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Intellia Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTLA
CUSIPN/A
Phone857-285-6200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.10 million
Book Value$5.52 per share

Profitability

Net Income$-99,530,000.00
Net Margins-239.98%

Miscellaneous

Employees211
Market Cap$1.02 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

How has Intellia Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NTLA stock has increased by 55.6% and is now trading at $19.79. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Intellia Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intellia Therapeutics.

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Intellia Therapeutics.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics Inc (NASDAQ:NTLA) issued its earnings results on Thursday, May, 7th. The company reported ($0.63) EPS for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.24. The company had revenue of $12.92 million for the quarter, compared to analysts' expectations of $21.98 million. Intellia Therapeutics had a negative return on equity of 40.89% and a negative net margin of 239.98%. Intellia Therapeutics's revenue for the quarter was up 23.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.49) EPS. View Intellia Therapeutics' earnings history.

What price target have analysts set for NTLA?

7 Wall Street analysts have issued 1 year price objectives for Intellia Therapeutics' shares. Their forecasts range from $16.00 to $57.50. On average, they anticipate Intellia Therapeutics' share price to reach $26.42 in the next twelve months. This suggests a possible upside of 33.5% from the stock's current price. View analysts' price targets for Intellia Therapeutics.

Has Intellia Therapeutics been receiving favorable news coverage?

News headlines about NTLA stock have been trending somewhat positive on Monday, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intellia Therapeutics earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutIntellia Therapeutics.

Who are some of Intellia Therapeutics' key competitors?

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Square (SQ), InVitae (NVTA), Advanced Micro Devices (AMD), Cisco Systems (CSCO) and Sangamo Therapeutics (SGMO).

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the following people:
  • Dr. John M. Leonard, Pres, CEO & Director (Age 62)
  • Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 46)
  • Mr. José E. Rivera, Exec. VP & Gen. Counsel (Age 53)
  • Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 33)
  • Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (13.81%), Sumitomo Mitsui Trust Holdings Inc. (14.51%), Nikko Asset Management Americas Inc. (13.81%), BlackRock Inc. (7.38%), State Street Corp (3.36%) and Morgan Stanley (1.26%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, Jean Francois Formela and Jose E Rivera. View institutional ownership trends for Intellia Therapeutics.

Which major investors are selling Intellia Therapeutics stock?

NTLA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Nuveen Asset Management LLC, Two Sigma Investments LP, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., and Bank of New York Mellon Corp. View insider buying and selling activity for Intellia Therapeutics.

Which major investors are buying Intellia Therapeutics stock?

NTLA stock was bought by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, BlackRock Inc., JPMorgan Chase & Co., Geode Capital Management LLC, Aigen Investment Management LP, State Street Corp, Los Angeles Capital Management & Equity Research Inc., and Two Sigma Advisers LP. View insider buying and selling activity for Intellia Therapeutics.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $19.79.

How big of a company is Intellia Therapeutics?

Intellia Therapeutics has a market capitalization of $1.02 billion and generates $43.10 million in revenue each year. The company earns $-99,530,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Intellia Therapeutics employs 211 workers across the globe.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is www.intelliatx.com.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.